HUMA Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides an in-depth financial analysis of Humacyte Inc (HUMA), detailing its revenue streams, profitability margins (gross, operating, and net), and efficiency metrics. It highlights the company's significant negative margins and compares its financial performance to competitors like AGEN and MOLN. The analysis aims to help investors understand HUMA's financial health relative to its industry peers.
Humacyte targets over 200 hospital access points for Symvess as VAC approvals surge and cost cuts extend cash runway
Humacyte is concentrating on expanding hospital access for its product Symvess, aiming for over 200 access points following recent Veterans Affairs Committee approvals. The company also implemented cost-cutting measures, extending its cash runway into the first quarter of 2026. This strategic approach includes leveraging positive clinical results to secure more widespread adoption.
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
Humacyte, Inc.'s stock (HUMA) fell by 2.44% in the latest trading session, underperforming the broader market indices like the S&P 500, Dow, and Nasdaq. The company is expected to report an EPS of -$0.1 and revenue of $1.23 million for the upcoming quarter, with full-year forecasts indicating a significant increase in revenue. Analysts' sentiment, as reflected by an unchanged Zacks Consensus EPS estimate and a Zacks Rank of #4 (Sell), suggests caution for investors.
Humacyte, Inc. (HUMA) Shares Decline Despite Overall Market Rise: The Reason Explained
Humacyte, Inc. (HUMA) shares dropped 2.44% to $0.59 in the latest trading session, contrasting with gains in the S&P 500, Dow, and Nasdaq. This decline follows a 43.3% drop over the past month, underperforming the Medical sector and S&P 500. Analysts project an EPS of -$0.1 and revenue of $1.23 million for the upcoming earnings, while the company currently holds a Zacks Rank of #4 (Sell), indicating potential underperformance.
Humacyte, Inc. (HUMA) Shares Decline Despite Overall Market Rise: The Reason Explained
Humacyte, Inc. (HUMA) shares declined by 2.44% to $0.59 while the broader market indices rose. The company has underperformed the Medical sector and S&P 500, with analysts expecting an EPS of -$0.1 and revenue of $1.23 million for the upcoming earnings report. Humacyte currently holds a Zacks Rank of #4 (Sell), reflecting lukewarm analyst sentiment.
Why BTIG cut its target on Humacyte (HUMA) but kept a bullish view on the bigger opportunity
The article discusses why BTIG lowered its price target on Humacyte (HUMA) but maintained a bullish outlook due to significant long-term potential. The report likely details the reasons for the target adjustment, such as short-term challenges or market conditions, while emphasizing the company's underlying value and future growth prospects.
Piper Sandler cuts Humacyte stock price target on weak sales
Piper Sandler has reduced its price target for Humacyte Inc. (NASDAQ:HUMA) from $3.00 to $1.00, maintaining a Neutral rating, due to disappointing fourth-quarter 2025 sales of its product Symvess, which significantly missed consensus estimates. Other firms like BTIG and TD Cowen have also lowered their price targets, highlighting commercial challenges and product launch performance concerns. Humacyte is awaiting crucial Phase 3 V012 study data in early June, which could expand its addressable market if successful.
Piper Sandler Cuts Humacyte (NASDAQ:HUMA) Price Target to $1.00
Piper Sandler has reduced its price target for Humacyte (NASDAQ:HUMA) from $3.00 to $1.00, while maintaining a "neutral" rating. This implies a potential upside of approximately 79% from the stock's last closing price of $0.56, which is near its 1-year low. The company recently reported negative EPS and a revenue miss, with significant negative margins and high leverage, though analyst sentiment remains mixed-to-positive with an average target of $6.88.
TD Cowen lowers Humacyte stock price target to $1 on launch concerns
TD Cowen lowered its price target for Humacyte Inc. (NASDAQ:HUMA) to $1.00 from $3.50, citing lower-than-expected fiscal year 2025 revenues and concerns regarding early U.S. launch trends for Symvess and the company's cash burn rate. Despite these concerns, the firm maintained a Buy rating due to optimism about Humacyte’s product pipeline. This follows a recent revenue miss in Q4 2025 and a similar price target adjustment by BTIG.
Why BTIG Cut Its Target on Humacyte (HUMA) but Kept a Bullish View on the Bigger Opportunity
BTIG maintained its Buy rating on Humacyte (HUMA) but lowered its price target from $6 to $3 following disappointing Q4 and full-year 2025 results, with quarterly revenue and unit sales missing estimates. Despite a choppy trauma launch for Symvess and elevated operating expenses, BTIG remains bullish on Humacyte due to commercial progress, a new purchase commitment from Saudi Arabia, and the larger opportunity presented by the dialysis access market. The firm awaits interim top-line results from the Phase 3 V012 study in dialysis access in Q2 2026.
5 Penny Stocks with Potential to Rise 1000 Percent
This article identifies Humacyte Inc. (NASDAQ: HUMA) as one of five penny stocks with potential for significant growth, despite recent mixed Q4 2025 results. Acknowledging sales and price per unit declines, BTIG maintained its Buy rating, citing commercial progress and a promising larger market opportunity in dialysis access. The article suggests that while Humacyte shows potential, some AI stocks may offer even higher returns with limited downside.
Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue Estimates
Humacyte, Inc. (HUMA) reported a Q4 loss of $0.13 per share, meeting analyst expectations, but missed revenue estimates significantly with $0.47 million against an expected $1.59 million. The company's shares have declined 19% year-to-date, reflecting an underperformance compared to the broader S&P 500. Analysts currently assign Humacyte a Zacks Rank #3 (Hold), suggesting its stock is expected to perform in line with the market.
Humacyte shares see BTIG price target cut to $3 on lower sales outlook
BTIG has lowered its price target for Humacyte (NASDAQ:HUMA) to $3 from $6, maintaining a Buy rating, following the company's Q4 2025 results. The company reported lower-than-expected revenue and continued losses, alongside a decrease in Symvess unit sales and price. Humacyte is facing financial challenges with high operating expenses and a significant negative gross profit margin, although it anticipates interim top-line results from its Phase 3 study for a dialysis access product in Q2 2026, which represents a larger market opportunity.
Humacyte 10-K: Revenue $2.04M, EPS $(0.26)
Humacyte reported fiscal 2025 revenue of $2.038 million and a net loss per share of $(0.26). The net loss significantly narrowed to $(40.833) million from $(148.701) million in the previous year, primarily due to $101.6 million net non-cash other income. The company also commenced U.S. commercial sales of Symvess, generating $1.4 million in product revenue for 2025.
Humacyte (NASDAQ:HUMA) Given "Buy" Rating at D. Boral Capital
D. Boral Capital has reissued a "Buy" rating for Humacyte (NASDAQ:HUMA) with a $25 price target, despite the company's recent Q4 revenue miss and a 12.3% drop in stock price. Analysts collectively hold a "Moderate Buy" rating for Humacyte, with an average price target of $7.71. The company recently appointed Rick McElheny as SVP of Business Development to accelerate partnerships and commercialization of its HAV pipeline.
Humacyte, Inc. (HUMA) reports Q4 loss, misses revenue estimates
This article reports that Humacyte, Inc. (HUMA) announced a loss for its fourth quarter, falling short of revenue estimates. Further financial details and reasons for the performance are not included in the provided content.
Humacyte (NASDAQ:HUMA) Issues Earnings Results
Humacyte (NASDAQ:HUMA) reported its earnings, with EPS matching estimates at ($0.13) but revenue falling short of expectations at $0.47 million against a consensus of $1.35 million. Despite a widened Q4 net loss, the company's FY25 net loss improved, and liquidity is supported by existing cash and recent financing. Key takeaways include commercial momentum for Symvess, potential non-commercial volume from U.S. Department of Defense funding, and progress in regulatory and pipeline catalysts.
Humacyte shares see BTIG price target cut to $3 on lower sales outlook
BTIG has lowered its price target for Humacyte stock to $3 from $6, while maintaining a Buy rating, following the company's Q4 2025 results which missed revenue estimates. The company reported $0.5 million in revenue and a loss per share of $0.13, alongside elevated operating expenses and a negative gross profit margin. Despite challenges in its trauma product launch, BTIG sees a larger opportunity in the dialysis access market, with Humacyte expecting top-line results from its Phase 3 study in Q2 2026.
From Pentagon funding to Saudi orders, Humacyte pushes Symvess abroad
Humacyte reported $2.0 million in revenue for 2025, including $1.4 million from Symvess sales, and announced significant international expansion efforts and progress in its clinical trials. The company secured a $1.475 million purchase commitment in Saudi Arabia for Symvess, submitted a Marketing Authorization Application in Israel, and received dedicated DoD funding for evaluating biologic vascular repair technologies. A key milestone includes the anticipated top-line interim results from its V012 Phase 3 hemodialysis study by early June 2026, which could lead to a BLA filing in the second half of 2026.
Humacyte Appoints Rick McElheny as Senior Vice President of Business Development
Humacyte, Inc. announced the appointment of Rick McElheny as Senior Vice President of Business Development. Mr. McElheny, with over 15 years of experience in corporate development in biopharma, will focus on expanding corporate collaborations to advance Humacyte's regenerative medicine pipeline. This strategic hire aims to accelerate the development and commercialization of the company's bioengineered human tissues.
Humacyte, Inc. (HUMA) Posts Fourth Quarter Loss, Falls Short of Revenue Expectations
Humacyte, Inc. (HUMA) reported a net loss of $0.13 per share for its latest quarter, matching Zacks' consensus estimate and improving from the prior year. However, the company's revenue of $0.47 million for the quarter ending December 2025 fell significantly short of expectations. With its stock down 19% year-to-date, investors are looking to future earnings projections and the Zacks Rank for insights into its market performance.
Humacyte Q4 2025 earnings preview
This article provides a Q4 2025 earnings preview for Humacyte. Due to the limited content provided, further details about the earnings expectations are unavailable.
Humacyte appoints Rick McElheny as SVP of business development By Investing.com
Humacyte, Inc. has announced the appointment of Rick McElheny as Senior Vice President of Business Development. McElheny brings over 15 years of experience in corporate development and alliance management in biopharmaceuticals and will focus on expanding collaborations for Humacyte's regenerative medicine pipeline. Despite recent FDA approval for its acellular tissue engineered vessel, the company is experiencing financial headwinds, including rapid cash burn and unprofitability, although analysts maintain a bullish outlook.
Humacyte Appoints Rick McElheny as Senior Vice President of Business Development
Humacyte, Inc. (Nasdaq: HUMA) has appointed Rick McElheny as Senior Vice President of Business Development. Mr. McElheny, with over 15 years of experience in corporate development, will lead efforts to expand corporate collaborations, accelerating the development and commercialization of Humacyte's regenerative medicine pipeline. His expertise is expected to be instrumental in forging strategic partnerships to bring the company's bioengineered tissues to patients globally.
Dealmaker behind $660M sale joins Humacyte to build partnerships
Humacyte (Nasdaq: HUMA) has appointed Rick McElheny as Senior Vice President of Business Development to lead efforts in expanding collaborations and commercializing its bioengineered tissue pipeline. McElheny brings over 15 years of experience in corporate development, including leading a $660 million sale and more than $250 million in out-licensing deals. This strategic hire aims to accelerate development and global availability of Humacyte's innovative products, including Symvess, and programs for coronary bypass graft surgery and Type 1 diabetes.
Humacyte Inc expected to post a loss of 13 cents a share - Earnings Preview
Humacyte Inc (HUMA) is expected to announce a loss of 13 cents per share, according to a Reuters earnings preview. This information is provided as part of a Refinitiv report on the company's financial outlook.
Fresenius Medical Care (HUMA) updates 8.4% beneficial stake in Humacyte
Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care AG have updated their beneficial ownership in Humacyte, Inc., reporting an 8.4% stake, or 18,312,735 shares. This percentage reflects a decrease from 9.5% previously, not due to selling shares, but because Humacyte issued additional outstanding shares in December 2025 and March 2026. Fresenius has not acquired or disposed of any Humacyte shares since its initial report in September 2021.
Humacyte secures $1.48M Symvess purchase commitment in Saudi Arabia
Humacyte has received a purchase commitment for $1.48 million for its bioengineered vessel, Symvess, from a new distributor in Saudi Arabia. This commitment follows the recent CE Mark approval for Symvess in Europe, indicating potential for broader international expansion. The agreement highlights the growing interest in advanced vascular access solutions for hemodialysis patients.
Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026
Humacyte, Inc. (NASDAQ: HUMA) is scheduled to announce its fourth quarter and year-end financial results for 2025 on March 27, 2026. Following the release, management will host a conference call and webcast to discuss these results and provide a business update. The event is scheduled for 4:30 p.m. ET.
Humacyte sets March 27 webcast for 2025 results and business update
Humacyte (Nasdaq: HUMA) announced it will release its fourth quarter and full-year 2025 financial results on March 27, 2026, followed by a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update. The company will discuss the progress of its commercial-stage biotechnology platform, including the FDA-approved Symvess for vascular trauma and ongoing late-stage trials. Investors will be keen to hear about the commercialization progress of Symvess and the updates on its clinical programs and financial position after recent financing activities.
HUMA (Humacyte, NASDAQ) pre-market 23 Mar 2026: earnings on Mar 27 could reset HUMA stock
Humacyte (HUMA) is trading pre-market at USD 0.8541 on NASDAQ, ahead of its Q4 2025 earnings release on March 27, 2026. This earnings report is a significant catalyst due to the company's negative EPS, recent high trading volume, and its early commercialization stage. Investors will be focused on clinical trial updates, cash runway details, and any commercial milestones as these could lead to substantial intraday volatility and reset the stock's valuation.
A Look At Humacyte (HUMA) Valuation As Symvess Secures Saudi Commitment And Israel Filing
Humacyte (HUMA) is gaining attention due to a US$1.475 million minimum purchase commitment for Symvess in Saudi Arabia and a Marketing Authorization Application in Israel, both aimed at vascular trauma treatment. Despite recent share price momentum, the company's valuation narrative suggests it is significantly undervalued at $22.83 per share compared to its current price of US$0.78. This optimistic outlook hinges on strong Symvess adoption, a shift to profitability, and successful dialysis trial timelines while acknowledging clear risks like cash burn.
If You Invested $1,000 in Humacyte Inc (HUMA)
This article analyzes the historical performance of a $1,000 investment in Humacyte Inc (HUMA) over various periods, showing significant losses compared to the S&P 500. It also provides a detailed overview of Humacyte Inc, highlighting its focus on bioengineered human tissues, particularly its Symvess product for vascular trauma, its regulatory approvals, clinical development pipeline, and commercialization efforts. The company's financial status, business model, and various regulatory designations for its ATEV programs are also discussed.
Humacyte’s Strategic Approach: Fundraising and Middle East Momentum Reduce Risks of Binary Clinical Results
Humacyte has adopted a dual strategy of securing a $20 million capital raise and expanding into the Middle East to mitigate the high risks associated with its clinical-stage status and reliance on binary clinical results. The capital raise provides critical liquidity and runway for commercialization and regulatory milestones in the US, particularly the hemodialysis BLA supplement and Phase 3 results. Concurrently, the Middle East expansion offers early market validation, modest revenue streams, and real-world data collection, diversifying its commercial approach and reducing overall execution risk.
Humacyte secures $1.48M Symvess purchase commitment in Saudi Arabia
Humacyte has received a purchase commitment for $1.48 million worth of Symvess from a healthcare provider in Saudi Arabia. This commitment is contingent on the regulatory approval of Symvess in the country. Symvess is a bioengineered human acellular vessel designed for vascular repair and reconstruction.
Humacyte secures $1.48M Symvess purchase commitment in Saudi Arabia
Humacyte has announced a significant $1.48 million purchase commitment for its bioengineered vessel, Symvess, from Saudi Health for its deployment in Saudi Arabia. This commitment follows the company's recent emergency use authorization from the FDA for Symvess to treat vascular trauma. The deal, facilitated by Humacyte's distributor, the Ministry of Defence Health Services, marks an important step for Symvess in reaching patients in need.
Is Humacyte (HUMA) Using Middle East Traction And Equity Issuance To Redefine Its Risk Profile?
Humacyte recently secured a binding purchase commitment for its Symvess product in Saudi Arabia and filed for a US$20 million stock offering and Marketing Authorization in Israel. These actions suggest the company is leveraging early commercial traction in the Middle East to fund expansion and training, aiming to transform its trauma-focused technology into an internationally adopted product. While these developments provide essential funding and signal international interest, the company still faces challenges with commercial adoption, cash burn, and potential dilution from future equity raises.
Humacyte raises $20M to back Symvess launch and Phase 3 readout
Humacyte has priced a registered direct offering of 25,000,000 shares to raise $20 million. The proceeds will fund the commercialization of Symvess for vascular trauma, support a Biologics License Application supplement in hemodialysis, and advance the pipeline ahead of an upcoming Phase 3 readout. Despite the capital raise, the market reacted negatively, with Humacyte's stock (HUMA) declining by 19.42% due to historical patterns of share price declines following equity offerings and potential dilution for existing shareholders.
Humacyte stock price target maintained at $6 by BTIG on Saudi deal
BTIG has maintained its Buy rating and $6.00 price target for Humacyte stock (NASDAQ:HUMA) despite the company's fiscal 2025 revenue of $2.0 million and fourth-quarter product sales falling short of estimates. The stock has seen a 68% decline over the past year and analysts note the company is burning through cash with weak gross profit margins. Recent developments include a $1.475 million purchase commitment for clinical evaluation in Saudi Arabia, a $20 million direct offering, and a Marketing Authorization Application in Israel, alongside funding from the U.S. Department of Defense.
Humacyte (HUMA) Projected to Post Quarterly Earnings on Friday
Humacyte (HUMA) is projected to report its Q4 2025 earnings before market open on Friday, March 27th, with analysts expecting an EPS loss of ($0.13) and revenue of approximately $1.349 million. The stock recently declined by 18.9% and is trading near its 52-week low, showing a high debt-to-equity ratio, yet institutional investors hold a significant stake. Wall Street maintains a "Moderate Buy" consensus rating with an average target price of $8.14.
Humacyte Announces $20 Million Registered Direct Offering
Humacyte (HUMA) announced a $20 million registered direct offering completed on March 19, 2026, through which it sold 25,000,000 shares at $0.80 per share. The net proceeds of $18.4 million will fund the commercialization of Symvess, support its Biologics License Application supplement in hemodialysis, advance pipeline development, and cover general corporate needs. Despite a "Neutral" rating from TipRanks’ AI Analyst, Spark, due to financial performance concerns, the funding aims to bolster the company's bioengineered tissue platform.
Humacyte (Nasdaq: HUMA) prices $20M registered direct stock sale
Humacyte (Nasdaq: HUMA) has priced a $20 million registered direct offering of 25,000,000 shares of common stock at $0.80 per share, expecting net proceeds of approximately $18.4 million. The funds will primarily support the commercialization of Symvess in vascular trauma, advance its hemodialysis Biologics License Application supplement and related Phase 3 activities, and pipeline development. The offering is anticipated to close around March 20, 2026, with Titan Partners acting as the sole placement agent.
Humacyte Secures $1.5M Saudi Order – Why Did HUMA Stock Crash To Record Low Today?
Humacyte secured a $1.5 million minimum purchase commitment from Saudi Arabia for its bioengineered blood vessel, Symvess, and is in talks to form a joint venture there. Despite this, the company's stock (HUMA) crashed over 20% to a record low after announcing a $20 million fundraising initiative by selling 25 million shares at a significant discount. The proceeds are intended to support Symvess commercialization and further development programs.
Humacyte Secures $1.5M Saudi Order – Why Did HUMA Stock Crash To Record Low Today?
Humacyte's stock crashed over 20% to an all-time low after announcing a $20 million fundraising round by selling 25 million shares at a 25% discount to its previous closing price. This happened despite simultaneously securing a $1.5 million minimum purchase commitment from Saudi Arabia for its bioengineered blood vessel, Symvess. The company plans to use the proceeds for Symvess commercialization, advancing its Biologics License Application, and ongoing clinical development, while also discussing a joint venture in Saudi Arabia.
HUMA Drops 19.6%: Sharp Downturn Triggered by $20M Sale Amid Market Turbulence
Humacyte (HUMA) shares experienced a significant 19.6% drop to $0.8519 after announcing a $20 million direct offering and a $1.475 million commitment for Symvess in Saudi Arabia. This decline, amplified by broader biotech sector weakness and dilution concerns, has pushed the stock near its 52-week low. Technical indicators suggest further bearish momentum, with traders advised to monitor key support levels and consider short-side strategies, especially as the sector struggles.
Humacyte (HUMA) halts $60M ATM as Symvess gains early sales and KSA deal
Humacyte (HUMA) has suspended its At-The-Market (ATM) equity program which allowed sales of up to $60 million in common stock, while early sales of its Symvess product reached $1.4 million with 61 units sold in 2025. The company also secured a $1.48 million Symvess purchase commitment in Saudi Arabia linked to a potential joint venture and filed for marketing authorization in Israel for vascular trauma. However, Humacyte continues to highlight significant risks including ongoing losses, future funding needs, and clinical trial uncertainties.
Saudi hospitals to evaluate Humacyte vessel under $1.475M deal
Humacyte received a binding commitment of $1.475 million for its Symvess product to initiate a clinical evaluation and outreach program in Saudi Arabian hospitals. The company will also provide training personnel and has exclusivity for commercialization negotiations in the KSA until July 2, 2026, while working towards a potential joint venture. Despite this positive development, Humacyte's stock (HUMA) saw an 11.42% decline, suggesting a negative market reaction.
Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
This article from MSN focuses on Humacyte, Inc. (HUMA) experiencing a larger stock price decline compared to the broader market. It aims to provide key information about the company in light of this performance.
Humacyte stock rating reiterated at Buy by D. Boral Capital
D. Boral Capital reiterated a Buy rating on Humacyte Inc. (NASDAQ:HUMA) with a $25.00 price target following the company's Marketing Authorization Application submission in Israel for Symvess, its tissue-engineered vessel for arterial trauma repair. The stock's current price is $1.14, representing substantial upside despite a 63% decline over the past year. This strategic move aims to expand into a region with significant trauma exposure, building on previous FDA approval and dedicated funding from the U.S. Department of Defense.
Humacyte submits marketing application for Symvess in Israel
Humacyte Inc. has submitted a Marketing Authorization Application to the Israel Ministry of Health for its acellular tissue engineered vessel, Symvess, aimed at arterial trauma repair. The company, which recently received FDA approval for Symvess, plans to expand into other international markets and is pursuing immediate availability in Israeli hospitals on a case-by-case basis. Despite facing typical biotech challenges like cash burn and unprofitability in the near term, analysts maintain varied price targets for the stock (NASDAQ: HUMA), which is currently trading at $1.14.
